

Will molecular targeted therapies become the new gold-standard in PC

Nisar Peter Malek

UEG Week Berlin 2025

Presentation

Digestive Oncology

Mechanisms & Personalised Medicine

Small Intestine & Nutrition

Pancreas

Surgery

October 7, 2025

This presentation reviews the current state of personalized medicine approaches in pancreatic ductal adenocarcinoma, including genomic profiling to identify targetable mutations and emerging therapies such as PARP inhibitors, checkpoint inhibitors, and novel K-RAS-targeted agents.

KEY POINTS

- The speaker states that approximately 90% of pancreatic cancers harbor K-RAS mutations, while 10% are K-RAS wild-type with different mutation profiles that may include rare targetable alterations such as ALK, ROS, or HER amplifications detected by sequencing.
- According to the speaker, maintenance therapy with the PARP inhibitor olaparib for BRCA2-mutant resected pancreatic cancer showed prolonged progression-free survival in a 2019 trial and is now part of clinical practice guidelines.
- The speaker reports that microsatellite-unstable pancreatic cancers showed response rates between 40 and 70% to checkpoint inhibitors in retrospective analyses, while PD-L1-positive but microsatellite-stable tumors do not respond.
- Expression profiling identifies basal-like and classical subtypes, and the speaker states that retrospective data suggest classical subtype patients respond better to folfinrox, with prospective stratification trials now underway.
- The speaker describes emerging K-RAS-targeted therapies, including specific G12 inhibitors showing high disease control rates in phase 1 studies and personalized RNA neoantigen vaccines developed by BioNTech from individual patient tumor tissue.
- In the German personalized medicine network, the speaker states that approximately 20 to 30% of the 12,000 patients presented to molecular tumor boards received targeted off-label treatments guided by genomic sequencing.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/dd97d83e-a82e-11f0-97e3-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.